Table 3.

Autoantibody ELISA titers and antibody-mediated CaMKII activation results in healthy subjects.

Patient #	α-D1R	α-D2R	α-Lysoganglioside-GM1	α-Tubulin	CaMKII Activation	ASO
1	500	16,000	160	1,000	93	87
2	1,000	16,000	160	1,000	100	221
3	2,000	4,000	80	500	99	166
4	1,000	16,000	80	500	98	79
5	500	2,000	200	500	89	513
6	500	2,000	100	250	94	271
7	1,000	2,000	200	250	98	487
8	500	2,000	100	500	92	70
9	2,000	4,000	200	1,000	106	421
10	1,000	8,000	100	1,000	99	78
11	1,000	2,000	80	500	88	240
12	1,000	4,000	80	500	96	200
13	1,000	4,000	80	500	94	200
14	500	2,000	160	250	86	200
15	2,000	8,000	80	500	99	320
16	1,000	4,000	80	1,000	53	25
17	2,000	8,000	320	2,000	95	35
18	1,000	2,000	80	500	79	63
19	1,000	4,000	80	500	87	200
20	2,000	8,000	80	1,000	80	25
21	4,000	8,000	1280	1,000	72	25
22	4,000	8,000	320	1,000	88	25
23	8,000	4,000	320	1,000	90	25
24	2,000	16,000	320	500	112	250
25	8,000	4,000	160	500	80	25
26	2,000	4,000	160	500	100	50
27	2,000	2,000	160	1,000	92	160
28	1,000	1,000	80	500	104	125
Number of Negative Results	24/28	24/28	27/28	27/28	28/28	16/28
Percent of Negative Results	85.7%	85.7%	96.4%	96.4%	100%	57.1%
Total Panel Specificity	19/28 healthy subjects were negative (67.8% specificity)

D1R, dopamine receptor D1, positive ≥ 4,000; D2R, dopamine receptor D2L, positive ≥ 16,000; Lyso, lysoganglioside GM1, positive ≥ 640; tubulin, positive ≥ 2,000; CaMKII, calcium/calmodulin-dependent protein kinase, positive ≥ 130%; ASO, anti-streptolysin O, positive ≥ 167.

Bold = positive result or neuronal panel-positive subject.